Pliant Therapeutics (PLRX) Enterprise Value (2019 - 2025)
Pliant Therapeutics (PLRX) has disclosed Enterprise Value for 7 consecutive years, with -$190.9 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value rose 46.32% to -$190.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$190.9 million, a 46.32% increase, with the full-year FY2025 number at -$190.9 million, up 46.32% from a year prior.
- Enterprise Value was -$190.9 million for Q4 2025 at Pliant Therapeutics, up from -$241.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$163.6 million in Q2 2022 to a low of -$577.3 million in Q1 2023.
- A 5-year average of -$339.7 million and a median of -$318.4 million in 2022 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: crashed 239.35% in 2023, then soared 46.32% in 2025.
- Pliant Therapeutics' Enterprise Value stood at -$200.6 million in 2021, then plummeted by 65.1% to -$331.2 million in 2022, then crashed by 49.23% to -$494.2 million in 2023, then rose by 28.03% to -$355.7 million in 2024, then skyrocketed by 46.32% to -$190.9 million in 2025.
- Per Business Quant, the three most recent readings for PLRX's Enterprise Value are -$190.9 million (Q4 2025), -$241.8 million (Q3 2025), and -$262.9 million (Q2 2025).